2011
Withdrawal related adverse effects of antipsychotic medication in a patient with first-episode schizophrenia
BARTEČEK, Richard, Tomáš KAŠPÁREK a Eva ČEŠKOVÁZákladní údaje
Originální název
Withdrawal related adverse effects of antipsychotic medication in a patient with first-episode schizophrenia
Název česky
Zmínění nežádoucích účinků antipsychotické medikace u pacientů s první epizodou schizofrenie
Autoři
BARTEČEK, Richard (203 Česká republika, garant, domácí), Tomáš KAŠPÁREK (203 Česká republika, domácí) a Eva ČEŠKOVÁ (203 Česká republika, domácí)
Vydání
Central European Journal of Medicine, Warsaw (Poland), Versita, 2011, 1895-1058
Další údaje
Jazyk
angličtina
Typ výsledku
Článek v odborném periodiku
Obor
30000 3. Medical and Health Sciences
Stát vydavatele
Polsko
Utajení
není předmětem státního či obchodního tajemství
Impakt faktor
Impact factor: 0.312
Kód RIV
RIV/00216224:14110/11:00053792
Organizační jednotka
Lékařská fakulta
UT WoS
000293708800022
Klíčová slova česky
schizofrenie; antipsychotika; zmírnění nežádoucích účinků
Klíčová slova anglicky
schizophrenia; antipsychotics; withdrawal related adverse effects
Příznaky
Mezinárodní význam
Změněno: 2. 2. 2012 16:12, Mgr. Michal Petr
Anotace
V originále
Withdrawal-emergent adverse effects of antipsychotics are an infrequently identified condition which can appear during antipsychotic dose reduction and medication change. In this paper, we present the case of severe extrapyramidal symptoms after a dose reduction of risperidone is presented. A patient, 23 years of age, was admitted to a health care facility due to an unexpected change in his behavior, with paranoid delusions, incoherent thinking, and significant anxiety. An initial risperidone treatment was soon changed to zuclopenhixol. Subsequently, severe extrapyramidal symptoms appeared, after which the medication was switched back to resperidone. Following this treatment, the patient left the health care facility and stopped the medication of his own volition. Psychotic symptoms and massive extrapyramidal symptoms again occurred. These symptoms subsided only slowly during a subsequent treatment with olanzapine. The development of adverse neurological effects together with a worsening of productive psychotic symptomatology may be explained by withdrawal of antipsychotic medication. These symptoms are often attributed to new medications, which are prematurely discontinued after the appearance of an adverse effect, but which are potentially beneficial to a patient, provided that enough time for a spontaneous subsidence of withdrawal-emergent effects is given. Any change in antipsychotic treatment should be carefully considered and thoroughly planned.